Free Trial
NASDAQ:SXTP

60 Degrees Pharmaceuticals Q1 2026 Earnings Report

60 Degrees Pharmaceuticals logo
$1.39 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$1.37 -0.02 (-1.73%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

60 Degrees Pharmaceuticals EPS Results

Actual EPS
-$1.28
Consensus EPS
-$0.76
Beat/Miss
Missed by -$0.52
One Year Ago EPS
N/A

60 Degrees Pharmaceuticals Revenue Results

Actual Revenue
$0.16 million
Expected Revenue
$0.44 million
Beat/Miss
Missed by -$272.91 thousand
YoY Revenue Growth
N/A

60 Degrees Pharmaceuticals Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
7:00AM ET

60 Degrees Pharmaceuticals Earnings Headlines

From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
60 Degrees Pharmaceuticals Announces 2025 Annual Results
See More 60 Degrees Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 60 Degrees Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 60 Degrees Pharmaceuticals and other key companies, straight to your email.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals (NASDAQ:SXTP), Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

View 60 Degrees Pharmaceuticals Profile